Strategic advisory for early- and mid-stage biotech, supporting your pipeline decisions and early product planning. Bringing PhD-level scientific judgment and nearly 20 years spanning blockbuster launches at Merck/MSD and early commercial and pipeline recommendations for the C-suite and board at AbCellera, to the decisions that shape your company's trajectory.
Explore My ServicesChoosing which asset or indication to prioritize, and how to develop it, are among the hardest decisions a biotech company faces. They rarely have an easy answer, and they rarely give the fast feedback that would let you course-correct in time. That avoidable risk is exactly what early planning targets: a commercial strategy built into your asset from the outset, and a pipeline shaped with intent, get you to clarity sooner, sharpen the case you'll make at each inflection point, and help you build a successful company.
I help you understand the commercial potential of your early-stage assets and make the strategic decisions that follow: which assets and indications to prioritize, and how to develop them in a way that's grounded in commercial reality and aligned with your company's strategic priorities.
My approach is built on close collaboration. I can take a project and run with it, but I'd rather check in on a regular basis, so we stay aligned on where to dig deep, where a high-level view is enough, and where to build efficiently on the work your company has already done. That alignment is what lets me tailor recommendations to your strategic priorities, and it makes it easier for you to present the final recommendation, with all its nuances, to your board, a potential business development partner, or an investor.
I develop strategies tailored to your company's situation, using rigorous analysis and judgment grounded in 20 years of industry experience.
At AbCellera, I built the early commercial strategy and valuations for preclinical assets and presented Go/No-Go investment recommendations to the C-suite. That work reshaped three Target Product Profiles (with implications for preclinical and clinical development), drove a strategic pivot in an autoimmune program's lead indication, and helped shape the corporate strategy for program selection. It built on 15+ years at Merck/MSD, supporting blockbuster launches like KEYTRUDA across medical affairs, market access, and pricing.
I bring that experience to your company, to give you confidence in your high-stakes pipeline decisions.
Heidi has an exceptional ability to see the long-term picture, shift programs away from potential commercial pitfalls, and present recommendations so a leadership team and board can act with confidence. I'd recommend her to any early-stage biotech that wants to make sharper pipeline and investment decisions.
Neil Aubuchon · Former Chief Commercial Officer, AbCellera · LinkedIn ↗